Role of late sodium channel current block in the management of atrial fibrillation

Cardiovascular Drugs and Therapy

Volumn 27, Issue 1, 2013, Pages 79-89

  Burashnikov, Alexander ^a   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

Action potential; Atrial fibrillation; Late sodium channel current; Pharmacology; Ranolazine

Indexed keywords

AMIODARONE; CALCIUM; FLECAINIDE; LIDOCAINE; MEXILETINE; PROPAFENONE; QUINIDINE; RANOLAZINE; SODIUM; SODIUM CHANNEL BLOCKING AGENT; TETRODOTOXIN; VERNAKALANT;

ANTIARRHYTHMIC ACTIVITY; CALCIUM CELL LEVEL; CHANNEL GATING; DRUG EFFICACY; HEART ATRIUM; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SODIUM CELL LEVEL; SODIUM CURRENT; SUPRAVENTRICULAR TACHYCARDIA;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HUMANS; MYOCYTES, CARDIAC; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TREATMENT OUTCOME;

EID: 84873057304     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6421-1     Document Type: Review

References (87)

1. Antzelevitch C, Belardinelli L, Wu L, Fraser H, Zygmunt AC, Burashnikov A, et al. Electrophysiologic properties and antiarrhythmic actions of a novel anti-anginal agent. J Cardiovasc Pharmacol Therapeut. 2004;9 Suppl 1:S65-83.
2. Undrovinas A, Maltsev VA. Late sodium current is a new therapeutic target to improve contractility and rhythm in failing heart. Cardiovasc Hematol Agents Med Chem. 2008;6:348-59.
3. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther. 2004;310:599-605.
4. Antoons G, Oros A, Beekman JDM, Engelen MA, Houtman MJC, Belardinelli L, et al. Late Na+ current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol. 2010;55:801-9.
5. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiological basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011;8:1281-90.
6. Gintant GA, Daytner NB, Cohen IS. Slow inactivation of a tetrodotoxin-sensitive current in canine cardiac Purkinje fibers. Biophys J. 1984;45:509-12.
7. Patlak JB, Ortiz M. Slow currents through single sodium channels of the adult rat heart. J Gen Physiol. 1985;86:89-104.
8. Attwell D, Cohen IS, Eisner DA, Ohba M, Ojeda C. The steady-state tetrodotoxin-sensitive ("window") sodium current in cardiac Purkinje fibers. Pflugers Arch. 1979;379:137-42.
9. Zygmunt AC, Eddlestone GT, Thomas GP, Nesterenko VV, Antzelevitch C. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol. 2001;281:H689-97.
10. Belardinelli L, Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J Suppl. 2006;8:A10-3.
11. Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther. 2012;133:311-23.
12. Persson F, Andersson B, Duker G, Jacobson I, Carlsson L. Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre. Eur J Pharmacol. 2007;558:133-43.
13. Li GR, Lau CP, Shrier A. Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. J Mol Cell Cardiol. 2002;34:1185-94.
14. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116:1449-57.
15. Kur block. Am J Physiol. 2004;286:H2393-400.
16. Sicouri S, Antzelevitch C. A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. The M cell. Circ Res. 1991;68:1729-41.
17. + currents in atrial fibrillation: effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010;55:2330-42.
18. Guo D, Young LH, Wu Y, Belardinelli L, Kowey PR, Yan GX. Increased late sodium current in left atrial myocytes of rabbits with left ventricular hypertrophy: its role in the genesis of atrial arrhythmias. Am J Physiol Heart Circ Physiol 2010.
19. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kuhlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res. 1999;44:121-31.
20. + current in a chronic dog model of atrial fibrillation. Circ Res. 1997;81:1045-52.
21. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954-68.
22. Akar JG, Everett TH, Ho R, Craft J, Haines DE, Somlyo AP, et al. Intracellular chloride accumulation and subcellular elemental distribution during atrial fibrillation. Circulation. 2003;107:1810-5.
23. + channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation. 2002;105:1208-13.
24. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, et al. Electrophysiologic effects of ranolazine: a novel anti-anginal agent with antiarrhythmic properties. Circulation. 2004;110:904-10.
25. Guo D, Lian J, Liu T, Cox R, Margulies KB, Kowey PR, et al. Contribution of late sodium current (I(Na-L)) to rate adaptation of ventricular repolarization and reverse use-dependence of QT-prolonging agents. Heart Rhythm. 2011;8:762-9.
26. Carmeliet E, Mubagwa K. Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Prog Biophys Mol Biol. 1998;70:1-72.
27. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. 2006;148:16-24.
28. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006;17:S161-77.
29. + current by ranolazine. Heart Rhythm. 2009;6:1625-31.
30. Zygmunt AC, Nesterenko VV, Rajamani S, Hu D, Barajas-Martinez H, Belardinelli L, et al. Mechanisms of atrial-selective block of sodium channel by ranolazine I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol. 2011;301:H1606-14.
31. Whalley DW, Wendt DJ, Grant AO. Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. PACE. 1995;18:1686-704.
32. Burashnikov A, Pourrier M, Gibson JK, Lynch JJ, Antzelevitch C. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel. Comparison with ranolazine and dl-sotaol. Circ Arrhythm Electrophysiol. 2012;5:400-8.
33. Wasserstrom JA, Salata JJ. Basis for tetrodotoxin and lidocaine effects on action potentials in dog ventricular myocytes. Am J Physiol. 1988;254:H1157-66.
34. Szel T, Koncz I, Jost N, Baczko I, Husti Z, Virag L, et al. Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations. Eur J Pharmacol. 2011;662:31-9.
35. Burashnikov A, Di Diego JM, Sicouri S, Ferreiro M, Carlsson L, Antzelevitch C. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm. 2008;5:1735-42.
36. Burashnikov A, Zygmunt AC, Di Diego JM, Linhardt G, Carlsson L, Antzelevitch C. AZD1305 exerts atrial-predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its re-induction in the dog. J Cardiovasc Pharmacol. 2010;56:80-90.
37. Nesterenko VV, Zygmunt AC, Rajamani S, Belardinelli L, Antzelevitch C. Mechanisms of atrial-selective block of Na+ channels by ranolazine: II. Insights from a mathematical model. Am J Physiol Heart Circ Physiol. 2011;301:H1615-24.
38. Burashnikov A, Petroski A, Hu D, Barajas-Martinez H, Antzelevitch C. Atrial-selective inhibition of sodium channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm. 2012;9:125-31.
39. Burashnikov A, Antzelevitch C. Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs. 2009;14:233-49.
40. Burashnikov A, Antzelevitch C. New development in atrial antiarrhythmic drug therapy. Nat Rev Cardiol. 2010;7:139-48.
41. Burashnikov A, Antzelevitch C. Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther. 2011;132:300-13.
42. Verheule S, Tuyls E, van Hunnik A, Kuiper M, Wang WQ, Dhalla A, et al. Effects of ranolazine in a goat model of lone atrial fibrillation. Circulation. 2009;120:S675.
43. Remme CA, Bezzina CR. Sodium channel (dys)function and cardiac arrhythmias. Cardiovasc Ther. 2010;28:287-94.
44. Moreno JD, Clancy CE. Pathophysiology of the cardiac late Na current and its potential as a drug target. J Mol Cell Cardiol. 2012;52:608-19.
45. Zipes DP. Electrophysiological remodeling of the heart owing to rate. Circulation. 1997;95:1745-8.
46. Antzelevitch C. Mechanisms of cardiac arrhythmias and conduction disturbances. In: Fuster V, O'Rourke RA, Walsh RA, Poole-Wilson P, editors. Hurst's the heart. 12th ed. New York: Mc-Graw-Hill; 2008. p. 913-45.
47. Wit AL, Rosen MR. Afterdepolarizations and triggered activity: distinction from automaticity as an arrhythmogenic mechanism. 1992;2113-64.
48. Burashnikov A, Antzelevitch C. Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation. 2003;107:2355-60.
49. Antzelevitch C. Electrical heterogeneity, cardiac arrhythmias, and the sodium channel. Circ Res. 2000;87:964-5.
50. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation. 1997;96:2038-47.
51. Kumar K, Nearing BD, Bartoli CR, Kwaku KF, Belardinelli L, Verrier RL. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J Cardiovasc Electrophysiol. 2008;19:1073-9.
52. Nieminen T, Nanbu DY, Datti IP, Vaz GR, Tavares CA, Pegler JR, et al. Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model. Heart Rhythm. 2011;8:608-14.
53. Morita N, Lee JH, Xie Y, Sovari A, Qu Z, Weiss JN, et al. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J Am Coll Cardiol. 2011;52:366-75.
54. Workman AJ, Smith GL, Rankin AC. Mechanisms of termination and prevention of atrial fibrillation by drug therapy. Pharmacol Ther. 2011;131:221-41.
55. Satoh T, Zipes DP. Cesium-induced atrial tachycardia degenerating into atrial fibrillation in dogs: atrial torsades de pointes? J Cardiovasc Electrophysiol. 1998;9:970-5.
56. Kirchhof P, Eckardt L, Franz MR, Monnig G, Loh P, Wedekind H, et al. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol. 2003;14:1027-33.
57. Zellerhoff S, Pistulli R, Monnig G, Hinterseer M, Beckmann BM, Kobe J, et al. Atrial arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. J Cardiovasc Electrophysiol. 2009;20:401-7.
58. Vincent GM. Atrial arrhythmias in the inherited long QT syndrome: laboratory quirk or clinical arrhythmia? J Cardiovasc Electrophysiol. 2003;14:1034-5.
59. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;12:1360-420.
60. van der Hooft CS, Heeringa J, van Herpen G, Kors JA, Kingma JH, Stricker BH. Drug-induced atrial fibrillation. J Am Coll Cardiol. 2004;44:2117-24.
61. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm. 2008;5:704-9.
62. Olesen MS, Yuan L, Liang B, Holst AG, Nielsen N, Nielsen JB, et al. High prevalence of long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial fibrillation. Circ Cardiovasc Genet. 2012;5:450-9.
63. Antzelevitch C, Shimizu W, Yan GX, Sicouri S, Weissenburger J, Nesterenko VV, et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 1999;10:1124-52.
64. Burashnikov A, Antzelevitch C. Prominent IKs in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations. J Cardiovasc Electrophysiol. 2002;13:172-7.
65. Burashnikov A, Antzelevitch C. Absence of early afterdepolarizations in canine atria under long QT syndrome. Heart Rhythm. 2011;8(5S):S328 (Abstract).
66. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation. 2000;101:2631-8.
67. Verheule S, Wilson E, Everett T, Shanbhag S, Golden C, Olgin J. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation. 2003;107:2615-22.
68. Roberts-Thomson KC, Stevenson I, Kistler PM, Haqqani HM, Spence SJ, Goldblatt JC, et al. The role of chronic atrial stretch and atrial fibrillation on posterior left atrial wall conduction. Heart Rhythm. 2009;6:1109-17.
69. Kistler PM, Sanders P, Dodic M, Spence SJ, Samuel CS, Zhao C, et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur Heart J. 2006;27:3045-56.
70. Burashnikov A, Di Diego JM, Moise NS, Kornreich BG, Belardinelli L, Antzelevitch C. Ranolazine causes atrial-selective electrophysiological effects and suppresses the induction of atrial fibrillation in a canine model of heart failue. Heart Rhythm 2012;9 (Abstract, in press).
71. Anyukhovsky EP, Sosunov EA, Chandra P, Rosen TS, Boyden PA, Danilo Jr P, et al. Age-associated changes in electrophysiologic remodeling: a potential contributor to initiation of atrial fibrillation. Cardiovasc Res. 2005;66:353-63.
72. Kistler PM, Sanders P, Fynn SP, Stevenson IH, Spence SJ, Vohra JK, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol. 2004;44:109-16.
73. Song Y, Shryock JC, Belardinelli L. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol. 2008;294:H2031-9.
74. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm. 2008;5:1019-26.
75. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of dronedarone and ranolazine to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56:1216-24.
76. Kumar K, Nearing BD, Carvas M, Nascimento BC, Acar M, Belardinelli L, et al. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol. 2009;20:796-802.
77. Carvas M, Nascimento BC, Acar M, Nearing BD, Belardinelli L, Verrier RL. Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart. J Cardiovasc Pharmacol. 2010;55:286-91.
78. Letienne R, Vie B, Puech A, Vieu S, Le Grand B, John GW. Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the cat cardiovascular system. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:464-71.
79. Sicouri S, Burashnikov A, Belardinelli L, Antzelevitch C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol. 2010;3:88-95.
80. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116:1647-52.
81. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J. 2008;8:175-81.
82. Murdock DK, Kersten M, Kaliebe J, Larrian G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a reveiw of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J. 2009;9:260-7.
83. Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011;108:673-6.
84. Murdock DK, Kaliebe J, Larrain G. The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series. Pacing Clin Electrophysiol. 2012;35:302-7.
85. Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol. 2012;110:673-7.
86. + channel blockers. Insights from mathematical models and experimental correlates. Am J Physiol Heart Circ Physiol. 2008;295:H1489-504.
87. Burashnikov A, Belardinelli L, Antzelevitch C. Atrial-selective sodium channel block strategy to suppress atrial fibrillation. Ranolazine versus propafenone. J Pharmacol Exp Ther. 2012;340:161-8.